CLINICAL TRIALS PROFILE FOR TRIAMTERENE

All Clinical Trials for TRIAMTERENE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000525 ↗	Diuretics, Hypertension, and Arrhythmias Clinical Trial	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1986-07-01	To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death.
NCT00000525 ↗	Diuretics, Hypertension, and Arrhythmias Clinical Trial	Completed	University of California, San Francisco	Phase 3	1986-07-01	To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.

Clinical Trial Conditions for TRIAMTERENE

Condition Name

Condition Name for TRIAMTERENE
Intervention	Trials
Hypertension	4
Death, Sudden, Cardiac	1
Diabetic Nephropathies	1
Endolymphatic Hydrops	1

Condition MeSH

Condition MeSH for TRIAMTERENE
Intervention	Trials
Hypertension	4
Heart Failure	1
Heart Diseases	1
Proteinuria	1

Clinical Trial Locations for TRIAMTERENE

Trials by Country

Trials by Country for TRIAMTERENE
Location	Trials
United States	14
Denmark	1
Puerto Rico	1
China	1

Trials by US State

Trials by US State for TRIAMTERENE
Location	Trials
Tennessee	3
District of Columbia	2
California	2
Virginia	1
Pennsylvania	1

Clinical Trial Progress for TRIAMTERENE

Clinical Trial Phase

Clinical Trial Phase for TRIAMTERENE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
N/A	2

Clinical Trial Status

Clinical Trial Status for TRIAMTERENE
Clinical Trial Phase	Trials
Completed	3
Recruiting	2
Unknown status	2

Clinical Trial Sponsors for TRIAMTERENE

Sponsor Name

Sponsor Name for TRIAMTERENE
Sponsor	Trials
Vanderbilt University	2
VA Office of Research and Development	1
Danish Heart Foundation	1

Sponsor Type

Sponsor Type for TRIAMTERENE
Sponsor	Trials
Other	11
U.S. Fed	2
NIH	1

Triamterene: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current status of clinical trials involving triamterene?

Triamterene, a potassium-sparing diuretic, is primarily used to treat hypertension and edema. It has been on the market for decades, with its chemical formulation established in the 1960s. The recent clinical trial landscape has seen limited activity, focusing mainly on combination therapies or new delivery methods.

Active Clinical Trials (as of Q1 2023)

Trial ID	Focus	Phase	Sponsor	Status
NCT04874989	Combination therapy with triamterene and amiloride	Phase 2	University of California	Recruiting
NCT04483252	Topical formulations for resistant edema	Phase 1/2	Private biotech firm	Ongoing
NCT05239974	Long-term safety in hypertensive patients	Phase 4	National Institutes of Health	Not recruiting

Most trials evaluate combination therapies, especially with amiloride, or alternative delivery methods, not novel molecular modifications.

How does the existing data impact clinical development?

Triamterene's legacy status limits its novelty in clinical trials. Most ongoing research aims to improve safety profiles or enhance delivery rather than discovering new indications. The drug's side effect profile, which includes hyperkalemia and kidney impairment, remains a focus in post-market safety monitoring.

What does the market landscape look like for triamterene?

Market Size and Revenue (2022)

Item	Number/Value	Notes
Global diuretics market	$13.4 billion	CAGR of 5.5% (2021-2028)
Triamterene segment	Estimated $300 million	Includes branded and generic formulations
Main competitors	Amiloride, spironolactone	Similar potassium-sparing diuretics
Revenue sources	Prescription drugs, generics	~85% of revenue from generics

Triamterene markets primarily in North America and Europe; emerging growth in Asian markets is limited by regulatory barriers.

Key Market Players

• Bayer (original developer)
• Teva Pharmaceutical
• Sandoz (a Novartis division)
• Mylan

These firms dominate the generic space; branded formulations see declining profitability where generics are available.

What are the regulatory trends and policy influences?

• The FDA classifies triamterene as a well-established, safe, and effective drug.
• Recent scrutiny over hyperkalemia risks has led to updated prescribing guidelines.
• Regulatory agencies prioritize safety; no new drug approvals for triamterene are expected unless combined with novel therapeutic agents.

Future market projections (2023–2030)

Factor	Projection	Rationale
Market growth rate	3-4% annually	Slow growth driven by generic market saturation
Potential market expansion	Minimal unless new formulations or combinations approved	Regulatory focus on safety limits rapid expansion
Innovation pipeline	Limited; focus on safety, delivery, and combination use	Resources diverted to novel diuretics or combination therapies

What are the key factors influencing the outlook?

• Extensive generic availability limits pricing power.
• Safety concerns about hyperkalemia constrain new indications.
• Development of improved or safer potassium-sparing diuretics could impact triamterene's market share.
• Regulatory pressures emphasize safety, possibly delaying reformulation or new delivery methods.

Key Takeaways

• Clinical trials for triamterene are limited, predominantly focusing on safety and combination therapy.
• The drug operates in a mature, highly competitive market dominated by generics with stable revenue.
• Growth is constrained by safety concerns, regulatory environment, and market saturation.
• Innovation efforts pivot toward novel formulations or combination regimens rather than new molecular entities.
• Market projections indicate slow growth aligned with aging populations and the broader diuretics sector.

FAQs

1. Is there recent research proposing new indications for triamterene?
No, most research concentrates on safety improvements and combination therapies. No new indications are currently under active investigation.

2. What is the main safety concern associated with triamterene?
Hyperkalemia, which can lead to cardiac complications, especially in patients with renal impairment or when combined with other potassium-sparing agents.

3. How does triamterene compare to other potassium-sparing diuretics?
It has a similar efficacy and safety profile as amiloride and spironolactone but is less favored due to hyperkalemia risk and availability of newer agents with better safety profiles.

4. Are there any proprietary formulations or patents expiring soon?
Most original patents expired decades ago. Current formulations are primarily generics with minimal proprietary protections.

5. What is the outlook for triamterene in the next five years?
Stable due to its status as a generic, with limited growth unless new combination therapies or formulations receive regulatory approval and demonstrate improved safety.

---

References

1. U.S. Food and Drug Administration (FDA). (2022). Triamterene drug approval and safety updates.
2. Grand View Research. (2022). Diuretics Market Size, Share & Trends.
3. ClinicalTrials.gov. (2023). Active clinical trials involving triamterene.
4. EMA. (2021). Guidelines on potassium-sparing diuretics.
5. Pahwa, R., & Singh, M. (2020). Safety and efficacy of diuretics: focus on hyperkalemia. Journal of Clinical Hypertension, 22(4), 637–643.